In this webinar recorded January 8, Scott Jordan showed how HealthiosXChange applies the highest standards in an effort to protect investors from common risks, though Direct Access, No Adverse Deal Selection, No “Orphan” Investments, and Total Transparency.

Of interest, H/X Incubator Direct has partnered with MATTER, a leading Incubator/Accelerator located in Chicago, along with noted pharmaceutical companies, including AbbVie, Astellas, and Takeda Pharmaceuticals.

MATTER will help connect partners with innovators and entrepreneurs, unite Chicago’s dispersed health technology community and accelerate the formation and growth of new businesses that can revolutionize healthcare. MATTER’s strategic partnerships will also give startups the rare opportunity to collaborate with and learn from industry leaders that can help them develop and launch their innovations.

MATTER’s mission is to proactively connect and promote collaboration between entrepreneurs, scientists, physicians and industry partners in order to bring next-generation products and services to market that improve quality of care and save lives.

If you are a Strategic (Large Pharma, Biotech, Medical Device) interested in how HealthiosXchange can assist your search and evaluation efforts, view this webinar.

HealthiosXchange is the premier online capital market dedicated exclusively to the global healthcare industry. Employing Crowdfunding as the cornerstone of a new paradigm in healthcare investing, HealthiosXchange offers direct access, from “seed” to “exit,” to the most promising healthcare companies in the world.

The past five years have been one of the more challenging periods for raising capital in the biotechnology industry, especially for early-stage companies. Numerous factors, including a challenging FDA environment upon NDA submission, long timelines to approval and the high rate of drug failure, have contributed to a dim venture capitalist view of the sector’s prospects. As a result, emerging growth biotechnology companies are increasingly pursuing alternative financing vehicles, including Equity Crowdfunding, to advance their drug development programs.